Şirket yükleniyor
Just reported
Q4 FY2026 results
From Cencora's results release of 4 Kasım 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
$88,35B
+%5,5 y/y
+%4,2 q/qGuided
—
No guide given
EPS, GAAP
Actual
$2,71
-%31 q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$906,8M
-%19 q/q
Guided
—
No guide given
Company outlook
Full year 2027
- EPS, adjusted$19,40 – $19,75First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Cencora is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Distribution
Graded A or B and worth $2B or more: A first, then the largest.
All 11 graded companies in its industry
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 Eki 2026CBGraded C, now B
MCKMckesson Corporation4 Kas 2026BAGraded B, now A
CVSCVS Health Corp4 Kas 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 Kas 2026BAGraded B, now A
BIIBBiogen Inc.28 Eki 2026BAGraded B, now A
Cencora, Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.
